KYMR
USDKymera Therapeutics Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$55.800
High
$61.580
Low
$55.660
Volume
0.77M
Company Fundamentals
Market Cap
4.3B
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
0.75M
Exchange
NGM
Currency
USD
52-Week Range
Related News
Guggenheim Assumes Kymera Therapeutics at Buy, Announces Price Target of $90
Guggenheim analyst Brad Canino assumes Kymera Therapeutics with a Buy rating and announces Price Target of $90.
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $75
BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics with a Buy and raises the price target from $59 to $75.
Mizuho Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $81
Mizuho analyst Joseph Catanzaro initiates coverage on Kymera Therapeutics with a Outperform rating and announces Price Target of $81.
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.